OIG Investigates NuVasive’s Medicare, Medicaid Claims
This article was originally published in The Gray Sheet
NuVasive revealed June 30 that it was recently subpoenaed by OIG as part of an investigation into potentially false or improper Medicare and Medicaid claims. The company’s stock price fell more than 12 percent July 31, the day after its second quarter earnings report.
You may also be interested in...
The spine device firm announced a definitive settlement with the Department of Justice, with a fine of $13.5 million, plus fees and accrued interest
The March 26 special fraud alert reiterates the HHS watchdog’s “longstanding position that the opportunity for a referring physician to earn a profit, including through an investment in an entity for which he or she generates business, could constitute illegal remuneration under the anti-kickback statute.”
Four major hip and knee implant manufacturers will pay the government a total of $311 million to settle anti-kickback claims resulting from a two-year Department of Justice and HHS investigation into the companies' financial relationships with surgeons, the New Jersey U.S. Attorney's office announced Sept. 27